Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13318)	1/14/1998 9:55:00 PM
From: Hippieslayer	Read Replies (1) \| Respond to of 32384

here we go again! Gern: Very interesting news, but no real drug and no indication that what was found will be able to be duplicated in real life diseases. +4 buck and higher srock price than lgnd. LGND: Entering into 98 with huge deal with LLY. Drugs that are ready to get FDA approval and more drugs ready for clinical trials. Yet the stock remains limp like the unknowning athlete that just ate food spiked with salt peter! Sorry, but that was the first analogy that came to my mind. Don't ask me why. Why can't Dan Rather Biased do a story on LGND? Why can't Peter "Barbara Streisand Dumped me" Jennings do the opening news item on LGND? And why can't Tom "i talk like I just got something stuck in my pant's zipper" Brokaw do a "in their own words" with DR? I want some biotech affirmative action here! Do you here what I'm saying! Ouch, I think i just popped a blood vessel.

To: Henry Niman who wrote (13318)	1/14/1998 11:53:00 PM
From: CYBERKEN	Read Replies (2) \| Respond to of 32384

Just a few thoughts re: the Leptin deal. It's now over a year overdue, and during that year, Ligand's value and prestige has increased several fold. While finishing the Lilly deal, they mentioned that they had "fallback" arrangements in case the deal didn't materialize. They seem to now have that situation with the mysterious and reluctant Leptin partner. The inability of the potential PARTNER to capture a Ligand collaboration so far is, IMO, a grave error on their part (not Ligand's) and calls into question whether we want our company to have to work with them through a long-term relationship. Ligand is no longer a desperate little development co scrounging for $$ from any big pharma which may be amused to listen. Therefore, if I'm Robinson, I might be more interested in shopping Leptin around for a more cooperative alliance partner. SO-- I'd slap a deal in front of them that gives me the sun, the stars and the moon, with 2 of the 3 up front. Then I'd stand at the door with one foot outside and a cab waiting, and indicate that if I heard anything more lengthy than "Yes, thank you, we readily accept!" in the next 20 seconds, it's over and I'm down the street. 9 chances in 10 say he gets that "yes". If it's "no", DR and his staff save a lot of valuable time. As I've said before: Biotech is about marvelous science. But more than anything else, it's about BUSINESS!